Loading…
Reported covered position: Rep. Susan Brooks-Senior Legislative Director & Legislative Director. Rep. Leonard Lance-Senior Legislative Director. Rep. Charlie Bass-Senior Legislative Assistant & Legislative Assistant. Sen. Judd Gregg-Legislative Assistant & Staff Assistant.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity, PBM reform, issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health, BIOSECURE Act, and the Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492).
EPIC Act of 2025
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2025 · first_quarter · Q1
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity, PBM reform, issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health, BIOSECURE Act, and the Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492).
Provisions related to the Continuing Appropriations and Other Matters Act, 2025; and issues related to budget reconciliation.
Source: Senate LDA
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity, PBM reform, issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health, BIOSECURE Act, and the Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492).
Rosa Parks Day Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). FY2024 Agriculture, FDA, and Related Agencies Appropriations (box warning report language). FY2025 MilCon VA Appropriations (PTSD screening). FY2025 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). BIOSECURE Act.
New Era of Preventing End-Stage Kidney Disease Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM reform, The New Eras of Preventing End-Stage Kidney Disease Act (HR 6790), 340B reform, FY2025 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD), FY2025 Agriculture, FDA, and Related Agencies Appropriations (box warning report language), FY2025 MilCon VA Appropriations (PTSD screening), FY2025 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD), and BIOSECURE Act.
New Era of Preventing End-Stage Kidney Disease Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity, PBM reform, The New Eras of Preventing End-Stage Kidney Disease Act (HR 6790) and rare nephrology issues, 340B reform, Psychedelics treatments for PTSD and mental health, and BIOSECURE Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity, PBM reform, issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health, and BIOSECURE Act, and the Ensuring Pathways to Innovate Cures (EPIC) Act, HR 7174.
Continuing Appropriations and Other Matters Act, 2025
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Provisions related to the Continuing Appropriations and Other Matters Act, 2025 (HR 9494)
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Rosa Parks Day Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). FY2024 Agriculture, FDA, and Related Agencies Appropriations (box warning report language).
Rosa Parks Day Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). FY2024 Agriculture, FDA, and Related Agencies Appropriations (box warning report language).
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Due Process Continuity of Care Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Due Process Continuity of Care Act
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: OTSUKA AMERICA PHARMACEUTICAL, INC.
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Issues related to tax reform efforts, issues stemming from the Tax Cuts and Jobs Act of 2017, and other corporate tax issues.
Veterans Affairs, Mental Health, and post-traumatic stress disorder (PTSD). Specifically, health care policies relating to mental health and PTSD. Veterans Affairs authorizations and appropriations issues related to mental health and PTSD.
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2024 · fourth_quarter · Q4
Provisions related to the Continuing Appropriations and Other Matters Act, 2025 (HR 9494)
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity, PBM reform, issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health, and BIOSECURE Act, and the Ensuring Pathways to Innovate Cures (EPIC) Act, HR 7174.
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2024 · third_quarter · Q3
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity, PBM reform, The New Eras of Preventing End-Stage Kidney Disease Act (HR 6790) and rare nephrology issues, 340B reform, Psychedelics treatments for PTSD and mental health, and BIOSECURE Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2024 · second_quarter · Q2
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM reform, The New Eras of Preventing End-Stage Kidney Disease Act (HR 6790), 340B reform, FY2025 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD), FY2025 Agriculture, FDA, and Related Agencies Appropriations (box warning report language), FY2025 MilCon VA Appropriations (PTSD screening), FY2025 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD), and BIOSECURE Act.
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2024 · first_quarter · Q1
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). FY2024 Agriculture, FDA, and Related Agencies Appropriations (box warning report language). FY2025 MilCon VA Appropriations (PTSD screening). FY2025 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). BIOSECURE Act.
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2023 · fourth_quarter · Q4
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). FY2024 Agriculture, FDA, and Related Agencies Appropriations (box warning report language).
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via OTSUKA AMERICA PHARMACEUTICAL, INC.
2023 · third_quarter · Q3
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). FY2024 Agriculture, FDA, and Related Agencies Appropriations (box warning report language).
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE